Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
New agents for bladder cancer.
Bellmunt J, Guix M. Bellmunt J, et al. Among authors: guix m. Ann Oncol. 2010 Oct;21 Suppl 7:vii56-8. doi: 10.1093/annonc/mdq367. Ann Oncol. 2010. PMID: 20943643 Free article. Review.
Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors.
Tabernero J, Rojo F, Marimón I, Voi M, Albanell J, Guix M, Vázquez F, Carulla J, Cooper M, Andreu J, Van Vreckem A, Bellmunt J, Manne V, Manning JA, Garrido C, Felip E, Del Campo JM, García M, Valverde S, Baselga J. Tabernero J, et al. Among authors: guix m. J Clin Oncol. 2005 Apr 10;23(11):2521-33. doi: 10.1200/JCO.2005.00.398. Epub 2005 Feb 14. J Clin Oncol. 2005. PMID: 15710949 Clinical Trial.
Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients.
Vidal J, Muinelo L, Dalmases A, Jones F, Edelstein D, Iglesias M, Orrillo M, Abalo A, Rodríguez C, Brozos E, Vidal Y, Candamio S, Vázquez F, Ruiz J, Guix M, Visa L, Sikri V, Albanell J, Bellosillo B, López R, Montagut C. Vidal J, et al. Among authors: guix m. Ann Oncol. 2017 Jun 1;28(6):1325-1332. doi: 10.1093/annonc/mdx125. Ann Oncol. 2017. PMID: 28419195 Free PMC article.
Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era.
Bellmunt J, Esteban E, Del Muro XG, Sepúlveda JM, Maroto P, Gallardo E, Del Alba AG, Etxaniz O, Guix M, Larriba JLG, Arranz JA, Redrado M, Calvo A. Bellmunt J, et al. Among authors: guix m. Eur Urol Oncol. 2021 Jun;4(3):502-505. doi: 10.1016/j.euo.2019.07.014. Epub 2019 Aug 30. Eur Urol Oncol. 2021. PMID: 31477526 Clinical Trial.
Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms.
Font A, Salazar R, Maurel J, Taron M, Ramirez JL, Tabernero J, Gallego R, Casado E, Manzano JL, Carcereny E, Guix M, Fernández-Llamazares J, Rosell R. Font A, et al. Among authors: guix m. Cancer Chemother Pharmacol. 2008 Nov;62(6):1075-83. doi: 10.1007/s00280-008-0700-3. Epub 2008 Mar 12. Cancer Chemother Pharmacol. 2008. PMID: 18335219 Clinical Trial.
Prognostic and Predictive Factors for Renal Cell Carcinoma.
Suárez C, Campayo M, Bastús R, Castillo S, Etxanitz O, Guix M, Sala N, Gallardo E. Suárez C, et al. Among authors: guix m. Target Oncol. 2018 Jun;13(3):309-331. doi: 10.1007/s11523-018-0557-2. Target Oncol. 2018. PMID: 29569164 Review.
86 results